About Mission Therapeutics

Sponsor retains sole responsibility for content.

Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of neurodegenerative disease, fibrosis, inflammation, cancer and other diseases of unmet need. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug ...

Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of neurodegenerative disease, fibrosis, inflammation, cancer and other diseases of unmet need. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis. The Company has raised $125M from investors Imperial Innovations, Pfizer Venture Investments, Roche Venture Fund, Sofinnova Partners, SR One and Woodford Patient Capital Trust. Mission is based at the Babraham Research Campus, Cambridge, UK.

Contact Mission Therapeutics

Phone Number
+44 (0) 1223 607340

More About Mission Therapeutics

Therapeutic Areas
  • Central Nervous System
  • Inflammation
  • Oncology
Technologies
  • Other
Company Type
  • Pharmaceutical
State of Ownership
  • Private
Sponsorship Group
  • Networker